Aβ-Protein Inhibitors Transforming Alzheimer’s Disease Treatment and Drug Development
The Changing Alzheimer’s Disease Treatment Landscape Alzheimer’s disease treatment has increasingly shifted from managing symptoms toward disease modification, particularly with therapies designed to target amyloid-beta (Aβ), a protein associated with plaque accumulation in the brain. The development of amyloid beta inhibitors has provided clinical evidence that removing amyloid can modestly slow cognitive and functional decline in selected patients with early disease. The emergence of Aβ protein inhibitors has therefore become an important milestone in the evolving therapeutic landscape. According to DelveInsight, LEQEMBI (lecanemab) and KISUNLA (donanemab) are currently the two Aβ-targeting therapies with full regulatory approval for early Alzheimer’s disease in the United States. These therapies target different forms of amyloid and have established an important benchmark for newer candidates. Approved and Emerging Aβ Protein Inhibitors LEQEMBI targets soluble amyloid proto...